FDA: Evusheld may lack efficacy against upcoming COVID-19 subvariants

Evusheld demonstrates reduced protection against the omicron subvariant BA.4.6, resulting in an increased risk for infection in those exposed to that COVID-19 strain, according to an updated FDA fact sheet.
In the revised fact sheet, the FDA warned that providers should be aware of an increased risk for developing COVID-19 when exposed to certain COVID-19 variants that are not neutralized by tixagevimab packaged with cilgavimab (Evusheld, AstraZeneca).
“Health care professionals should inform patients of this risk and advise patients who develop signs or symptoms of COVID-19 to test for

Evusheld demonstrates reduced protection against the omicron subvariant BA.4.6, resulting in an increased risk for infection in those exposed to that COVID-19 strain, according to an updated FDA fact sheet.
In the revised fact sheet, the FDA warned that providers should be aware of an increased risk for developing COVID-19 when exposed to certain COVID-19 variants that are not neutralized by tixagevimab packaged with cilgavimab (Evusheld, AstraZeneca).
“Health care professionals should inform patients of this risk and advise patients who develop signs or symptoms of COVID-19 to test for